Login / Signup

SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.

Georgina ArrambideMiguel Ángel Llaneza-GonzálezLucienne Costa-Frossard FrançaVirginia Meca-LallanaEva Fernández- DíazIrene Moreno-TorresJose Manuel García-DomínguezGloria Ortega-SueroLucía Ayuso-PeraltaMayra Gómez-MorenoJavier J Sotoca-FernándezAna Belén Caminero-RodríguezLuis A Rodríguez de AntonioMarcial Corujo-SuárezMaría A Otano-MartínezFrancisco Carlos Pérez-MirallesVirginia Reyes-GarridoTeresa Ayuso-BlancoJosé Jesús Balseiro-GómezMercedes Muñoz-PasadasInmaculada Pérez-MolinaCarmen Arnal-GarcíaÁngela Domingo-SantosCristina Guijarro-CastroCristina Íñiguez-MartínezNieves Téllez LaraFernando Castellanos-PinedoTamara Castillo-TriviñoDebora María Cerdán-SantacruzÁngel Pérez SempereBerta Sebastián TorresAmaya Álvarez de ArcayaEva Costa-ArpínEduardo Durán-FerrerasMarta Fragoso-MartínezMontserrat González-PlatasLamberto Landete PascualJorge Millán-PascualCelia Oreja-GuevaraJosé E Meca-Lallana
Published in: Neurology(R) neuroimmunology & neuroinflammation (2021)
This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease.
Keyphrases
  • multiple sclerosis
  • mass spectrometry
  • coronavirus disease
  • white matter
  • sars cov
  • ms ms
  • respiratory syndrome coronavirus
  • early onset
  • mesenchymal stem cells
  • stem cells
  • drug induced
  • replacement therapy